Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ESSA Pharma's Enterprise Value is $-100.10 Mil.
ESSA Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-20.89 Mil. Therefore, ESSA Pharma's EV-to-OCF for today is 4.79.
The historical rank and industry rank for ESSA Pharma's EV-to-OCF or its related term are showing as below:
EPIX'
s EV-to-OCF Range Over the Past 10 Years
Min: 4.79 Med: 0 Max: 4.79
Current: 4.79
During the past 11 years, the highest EV-to-OCF of ESSA Pharma was 4.79. The lowest was 4.79. And the median was .
EPIX's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.68
vs EPIX: 4.79
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ESSA Pharma's PE Ratio (TTM) for today is calculated as:
ESSA Pharma's share price for today is $0.2012.
ESSA Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ESSA Pharma EV-to-OCF Related Terms
ESSA Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ESSA Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ESSA Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ESSA Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ESSA Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's EV-to-OCF falls into.
ESSA Pharma's current Enterprise Value is $-100.10 Mil.
ESSA Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma (EPIX) has a EV-to-OCF of 4.79 as of Aug. 24, 2026. Over the past decade, ESSA Pharma's EV-to-OCF has ranged from 4.79 to 4.79.
Is ESSA Pharma's EV-to-OCF too high?
ESSA Pharma's current EV-to-OCF is 4.79. Over the past 10 years, this metric has ranged from a low of 4.79 to a high of 4.79. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's EV-to-OCF compare to SLXN and NLSP?
ESSA Pharma's EV-to-OCF of 4.79 can be compared against companies in the Biotechnology industry. Historically, ESSA Pharma's own EV-to-OCF has ranged from 4.79 to 4.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ESSA Pharma's current EV-to-OCF is 4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current EV-to-OCF of 4.79. The current EV-to-OCF is 4.79. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current EV-to-OCF is 4.79 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score
Get the complete analysis for EPIX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPIX has been successfully added to your 
